What's new in IBD treatment? Gain insights on advances in the medical and dietary management of IBD

A discussion of the latest developments in the medical and dietary management of IBD. Video Content: 00:00 - Intro/Welcome 04:27 - Discussing Benefits, Risks of Treatment, & Uncontrolled Disease with Patients. 05:08 - Starting with Crohn’s Disease 06:23 - CD Clinical Symptoms May Not Correlate with Intestinal Inflammation 08:10 - Skyrizi (Risankizumab) for Crohn’s Disease: An IL-23 Inhibitor 10:09 - Skyrizi (Clinical Remission at Week 52) 13:19 - Skyrizi (Fortify AEs) 16:16 - Skyrizi (Frequency of Dosing Convenience) 16:36 - New Drugs For Ulcerative Colitis: Zeposia & Rinvoq 17:42 - Disease Progression Necessitates Changes in UC Treatment 19:29 - Ulcerative Colitis: Sigmoidoscopy/Colonoscopy: What Does Inflammation Look Like? 20:17 - MAYO Endoscopy Subscores 21:59 - Zeposia (Ozanimod): A S1P Modulator 24:11 - Zeposia (Symptomatic Response & Remission) 25:22 - Zeposia (Control is Possible Without the use of Corticosteroids) 25:22 - Zeposia (Drug Discontinuation Rates Less Than Placebo) 28:03 - Rinvoq (Upadacitinib) for Ulcerative Colitis: A Jak-Kinase Inhibitor 29:44 - Rinvoq (Patient-Reported Outcomes Data by Day) 30:50 - Rinvoq (Clinical Remission at Week 8) 32:45 - Rinvoq (AEs of Special Interest) 34:57 - Treatment Summary 38:13 - Advances in the Role of Diet in IBD 41:53 - Fiber: Friend or Foe? 44:40 - Eternal Nutrition 46:10 - Recommended Dietary Patterns in CD & UC 48:16 - Specific Carbohydrate Diet (SCD) 49:52 - Mediterranean Diet 52:04 - Nutritional Takeaways 53:09 - Q&A